2023 was an excellent year for Devyser, and a range of our products appeared in scientific journals...
Devyser Diagnostics AB announces today an article titled “Detection of donor-derived cell-free DNA...
“Devyser is able to report strong sales growth and record high gross margins for the fourth...
Over the past decade, there has been a wealth of research investigating the ideal approach to RHD...
Devyser Genomic Laboratories, Devyser's US-based CLIA-certified laboratory, has signed its first...
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for...
Devyser Diagnostics AB has entered an in vitro diagnostic development agreement with Illumina, Inc....
On October 26th, we hosted an insightful webinar by Prof. Milan Macek (M.D., DSc.), where he...
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for...
Devyser has been awarded a tender for Devyser RHD, its product for non-invasive fetal RHD status in...
